B-intervention	0	12	Preoperative
I-intervention	13	16	MRI
O	17	20	and
O	21	29	surgical
O	30	40	management
O	41	43	in
O	44	52	patients
O	53	57	with
O	58	69	nonpalpable
O	70	76	breast
O	77	83	cancer
O	83	84	:
O	85	88	the
O	89	94	MONET
O	95	96	-
O	97	107	randomised
O	108	118	controlled
O	119	124	trial
O	124	125	.

O	126	128	We
O	129	138	evaluated
O	139	146	whether
O	147	157	performing
O	158	166	contrast
O	166	167	-
O	167	175	enhanced
O	176	182	breast
O	183	186	MRI
O	187	189	in
O	190	198	addition
O	199	201	to
O	202	213	mammography
O	214	217	and
O	217	218	/
O	218	220	or
O	221	231	ultrasound
O	232	234	in
B-eligibility	235	243	patients
I-eligibility	244	248	with
I-eligibility	249	260	nonpalpable
I-eligibility	261	271	suspicious
I-eligibility	272	278	breast
I-eligibility	279	286	lesions
O	287	295	improves
O	296	302	breast
O	303	309	cancer
O	310	320	management
O	320	321	.

O	322	325	The
O	326	331	MONET
O	332	333	-
O	334	339	study
O	340	341	(
O	341	343	MR
O	344	355	mammography
O	356	358	of
O	359	370	nonpalpable
O	371	377	breast
O	378	385	tumours
O	385	386	)
O	387	389	is
O	390	391	a
O	392	402	randomised
O	403	413	controlled
O	414	419	trial
O	420	422	in
O	423	431	patients
O	432	436	with
O	437	438	a
O	439	450	nonpalpable
O	451	457	BIRADS
O	458	459	3
O	459	460	-
O	460	461	5
O	462	468	lesion
O	468	469	.

O	470	478	Patients
O	479	483	were
O	484	492	randomly
O	493	501	assigned
O	502	504	to
O	505	512	receive
B-control	513	520	routine
I-control	521	528	medical
I-control	529	533	care
O	533	534	,
O	535	544	including
O	545	556	mammography
O	556	557	,
O	558	568	ultrasound
O	569	572	and
O	573	579	lesion
O	580	588	sampling
O	589	591	by
O	592	597	large
O	598	602	core
O	603	609	needle
O	610	616	biopsy
O	617	619	or
O	620	630	additional
O	631	634	MRI
O	635	644	preceding
O	645	651	biopsy
O	651	652	.

O	653	661	Patients
O	662	666	with
O	667	673	cancer
O	674	678	were
O	679	687	referred
O	688	691	for
O	692	699	surgery
O	699	700	.

O	701	708	Primary
O	709	712	end
O	712	713	-
O	713	718	point
O	719	722	was
O	723	726	the
B-outcome-Measure	727	731	rate
I-outcome-Measure	732	734	of
I-outcome-Measure	735	745	additional
I-outcome-Measure	746	754	surgical
I-outcome-Measure	755	765	procedures
I-outcome-Measure	766	767	(
I-outcome-Measure	767	769	re
I-outcome-Measure	769	770	-
I-outcome-Measure	770	779	excisions
I-outcome-Measure	780	783	and
I-outcome-Measure	784	794	conversion
I-outcome-Measure	795	797	to
I-outcome-Measure	798	808	mastectomy
I-outcome-Measure	808	809	)
O	810	812	in
O	813	821	patients
O	822	826	with
O	827	828	a
O	829	840	nonpalpable
O	841	847	breast
O	848	854	cancer
O	854	855	.

B-total-participants	856	860	Four
I-total-participants	861	868	hundred
I-total-participants	869	872	and
I-total-participants	873	881	eighteen
O	882	890	patients
O	891	895	were
O	896	906	randomised
O	906	907	,
B-intervention-participants	908	911	207
O	912	920	patients
O	921	925	were
O	926	935	allocated
O	936	938	to
O	939	942	MRI
O	942	943	,
O	944	947	and
B-control-participants	948	951	211
O	952	960	patients
O	961	963	to
O	964	967	the
O	968	975	control
O	976	981	group
O	981	982	.

O	983	985	In
O	986	989	the
O	990	993	MRI
O	994	999	group
B-iv-bin-abs	1000	1002	74
O	1003	1011	patients
O	1012	1015	had
O	1016	1018	83
B-outcome	1019	1028	malignant
I-outcome	1029	1036	lesions
O	1036	1037	,
O	1038	1046	compared
O	1047	1049	to
B-cv-bin-abs	1050	1052	75
O	1053	1061	patients
O	1062	1066	with
O	1067	1069	80
O	1070	1079	malignant
O	1080	1087	lesions
O	1088	1090	in
O	1091	1094	the
O	1095	1102	control
O	1103	1108	group
O	1108	1109	.

O	1110	1113	The
B-outcome	1114	1121	primary
I-outcome	1122	1128	breast
I-outcome	1129	1139	conserving
I-outcome	1140	1147	surgery
I-outcome	1148	1149	(
I-outcome	1149	1152	BCS
I-outcome	1152	1153	)
I-outcome	1154	1158	rate
O	1159	1162	was
O	1163	1170	similar
O	1171	1173	in
O	1174	1178	both
O	1179	1185	groups
O	1185	1186	;
B-iv-bin-percent	1187	1189	68
I-iv-bin-percent	1189	1190	%
O	1191	1193	in
O	1194	1197	the
O	1198	1201	MRI
O	1202	1207	group
O	1208	1214	versus
B-cv-bin-percent	1215	1217	66
I-cv-bin-percent	1217	1218	%
O	1219	1221	in
O	1222	1225	the
O	1226	1233	control
O	1234	1239	group
O	1239	1240	.

O	1241	1244	The
B-outcome	1245	1251	number
I-outcome	1252	1254	of
I-outcome	1255	1257	re
I-outcome	1257	1258	-
I-outcome	1258	1267	excisions
O	1268	1277	performed
O	1278	1285	because
O	1286	1288	of
O	1289	1297	positive
O	1298	1307	resection
O	1308	1315	margins
O	1316	1321	after
O	1322	1329	primary
O	1330	1333	BCS
O	1334	1337	was
O	1338	1347	increased
O	1348	1350	in
O	1351	1354	the
O	1355	1358	MRI
O	1359	1364	group
O	1364	1365	;
B-iv-bin-abs	1366	1368	18
O	1368	1369	/
B-intervention-participants	1369	1371	53
O	1372	1373	(
B-iv-bin-percent	1373	1375	34
I-iv-bin-percent	1375	1376	%
O	1376	1377	)
O	1378	1386	patients
O	1387	1389	in
O	1390	1393	the
O	1394	1397	MRI
O	1398	1403	group
O	1404	1410	versus
B-cv-bin-abs	1411	1412	6
O	1412	1413	/
B-control-participants	1413	1415	50
O	1416	1417	(
B-cv-bin-percent	1417	1419	12
I-cv-bin-percent	1419	1420	%
O	1420	1421	)
O	1422	1424	in
O	1425	1428	the
O	1429	1436	control
O	1437	1442	group
O	1443	1444	(
O	1444	1445	p
O	1445	1446	=
O	1446	1447	0
O	1447	1448	.
O	1448	1451	008
O	1451	1452	)
O	1452	1453	.

O	1454	1457	The
B-outcome	1458	1464	number
I-outcome	1465	1467	of
I-outcome	1468	1479	conversions
I-outcome	1480	1482	to
I-outcome	1483	1493	mastectomy
O	1494	1497	did
O	1498	1501	not
O	1502	1508	differ
O	1509	1522	significantly
O	1523	1530	between
O	1531	1537	groups
O	1537	1538	.

O	1539	1546	Overall
O	1546	1547	,
O	1548	1551	the
B-outcome	1552	1556	rate
I-outcome	1557	1559	of
I-outcome	1560	1562	an
I-outcome	1563	1573	additional
I-outcome	1574	1582	surgical
I-outcome	1583	1595	intervention
O	1596	1597	(
O	1597	1600	BCS
O	1601	1604	and
O	1605	1615	mastectomy
O	1616	1624	combined
O	1624	1625	)
O	1626	1631	after
O	1632	1639	initial
O	1640	1646	breast
O	1647	1657	conserving
O	1658	1665	surgery
O	1666	1669	was
B-iv-bin-abs	1670	1672	24
O	1672	1673	/
B-intervention-participants	1673	1675	53
O	1676	1677	(
B-iv-bin-percent	1677	1679	45
I-iv-bin-percent	1679	1680	%
O	1680	1681	)
O	1682	1684	in
O	1685	1688	the
O	1689	1692	MRI
O	1693	1698	group
O	1699	1705	versus
B-cv-bin-abs	1706	1708	14
O	1708	1709	/
B-control-participants	1709	1711	50
O	1712	1713	(
B-cv-bin-percent	1713	1715	28
I-cv-bin-percent	1715	1716	%
O	1716	1717	)
O	1718	1720	in
O	1721	1724	the
O	1725	1732	control
O	1733	1738	group
O	1739	1740	(
O	1740	1741	p
O	1741	1742	=
O	1742	1743	0
O	1743	1744	.
O	1744	1747	069
O	1747	1748	)
O	1748	1749	.

O	1750	1758	Addition
O	1759	1761	of
O	1762	1765	MRI
O	1766	1768	to
O	1769	1776	routine
O	1777	1785	clinical
O	1786	1790	care
O	1791	1793	in
O	1794	1802	patients
O	1803	1807	with
O	1808	1819	nonpalpable
O	1820	1826	breast
O	1827	1833	cancer
O	1834	1837	was
O	1838	1851	paradoxically
O	1852	1862	associated
O	1863	1867	with
O	1868	1870	an
O	1871	1880	increased
B-outcome	1881	1883	re
I-outcome	1883	1884	-
I-outcome	1884	1892	excision
I-outcome	1893	1897	rate
O	1897	1898	.

O	1899	1905	Breast
O	1906	1909	MRI
O	1910	1916	should
O	1917	1920	not
O	1921	1923	be
O	1924	1928	used
O	1929	1938	routinely
O	1939	1942	for
O	1943	1955	preoperative
O	1956	1960	work
O	1960	1961	-
O	1961	1963	up
O	1964	1966	of
O	1967	1975	patients
O	1976	1980	with
O	1981	1992	nonpalpable
O	1993	1999	breast
O	2000	2006	cancer
O	2006	2007	.
